Nature Communications (Oct 2018)
Phenome-wide association studies across large population cohorts support drug target validation
- Dorothée Diogo,
- Chao Tian,
- Christopher S. Franklin,
- Mervi Alanne-Kinnunen,
- Michael March,
- Chris C. A. Spencer,
- Ciara Vangjeli,
- Michael E. Weale,
- Hannele Mattsson,
- Elina Kilpeläinen,
- Patrick M. A. Sleiman,
- Dermot F. Reilly,
- Joshua McElwee,
- Joseph C. Maranville,
- Arnaub K. Chatterjee,
- Aman Bhandari,
- Khanh-Dung H. Nguyen,
- Karol Estrada,
- Mary-Pat Reeve,
- Janna Hutz,
- Nan Bing,
- Sally John,
- Daniel G. MacArthur,
- Veikko Salomaa,
- Samuli Ripatti,
- Hakon Hakonarson,
- Mark J. Daly,
- Aarno Palotie,
- David A. Hinds,
- Peter Donnelly,
- Caroline S. Fox,
- Aaron G. Day-Williams,
- Robert M. Plenge,
- Heiko Runz
Affiliations
- Dorothée Diogo
- Merck Sharp & Dohme
- Chao Tian
- 23andMe Inc
- Christopher S. Franklin
- Genomics plc
- Mervi Alanne-Kinnunen
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Michael March
- The Children’s Hospital of Philadelphia and University of Pennsylvania
- Chris C. A. Spencer
- Genomics plc
- Ciara Vangjeli
- Genomics plc
- Michael E. Weale
- Genomics plc
- Hannele Mattsson
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Elina Kilpeläinen
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Patrick M. A. Sleiman
- The Children’s Hospital of Philadelphia and University of Pennsylvania
- Dermot F. Reilly
- Merck Sharp & Dohme
- Joshua McElwee
- Merck Sharp & Dohme
- Joseph C. Maranville
- Merck Sharp & Dohme
- Arnaub K. Chatterjee
- Merck Sharp & Dohme
- Aman Bhandari
- Merck Sharp & Dohme
- Khanh-Dung H. Nguyen
- Biogen, Research and Early Development
- Karol Estrada
- Biogen, Research and Early Development
- Mary-Pat Reeve
- Eisai
- Janna Hutz
- Eisai
- Nan Bing
- Pfizer
- Sally John
- Biogen, Research and Early Development
- Daniel G. MacArthur
- Broad Institute of MIT and Harvard
- Veikko Salomaa
- National Institute for Health and Welfare
- Samuli Ripatti
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Hakon Hakonarson
- The Children’s Hospital of Philadelphia and University of Pennsylvania
- Mark J. Daly
- Broad Institute of MIT and Harvard
- Aarno Palotie
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- David A. Hinds
- 23andMe Inc
- Peter Donnelly
- Genomics plc
- Caroline S. Fox
- Merck Sharp & Dohme
- Aaron G. Day-Williams
- Merck Sharp & Dohme
- Robert M. Plenge
- Merck Sharp & Dohme
- Heiko Runz
- Merck Sharp & Dohme
- DOI
- https://doi.org/10.1038/s41467-018-06540-3
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
Testing the association between genetic variants and a range of phenotypes can assist drug development. Here, in a phenome-wide association study in up to 697,815 individuals, Diogo et al. identify genotype–phenotype associations predicting efficacy, alternative indications or adverse drug effects.
